[Recent developments in antipsychotic medication].
The development of new neuroleptics aims to reduce unwanted extrapyramidal motor side effects as well as the non-response rate, and to achieve a greater effect on negative symptoms. Preferential binding of neuroleptics to D2-receptors in the limbic system, as well as the combination of dopamine D2- and serotonin S2-antagonism proved to be effective. A potent D2-S2-antagonism as was realized with positive results in risperidone serves as a model for a whole class of new neuroleptics.